Cargando…
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791256/ https://www.ncbi.nlm.nih.gov/pubmed/33437810 http://dx.doi.org/10.21037/atm-20-2656 |
| _version_ | 1783633573054513152 |
|---|---|
| author | Borcoman, Edith Le Tourneau, Christophe |
| author_facet | Borcoman, Edith Le Tourneau, Christophe |
| author_sort | Borcoman, Edith |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7791256 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77912562021-01-11 Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer Borcoman, Edith Le Tourneau, Christophe Ann Transl Med Editorial Commentary AME Publishing Company 2020-12 /pmc/articles/PMC7791256/ /pubmed/33437810 http://dx.doi.org/10.21037/atm-20-2656 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Borcoman, Edith Le Tourneau, Christophe Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer |
| title | Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer |
| title_full | Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer |
| title_fullStr | Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer |
| title_full_unstemmed | Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer |
| title_short | Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer |
| title_sort | keynote-158 study, fda granted accelerated approval of pembrolizumab for the treatment of patients with advanced pd-l1-positive cervical cancer |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791256/ https://www.ncbi.nlm.nih.gov/pubmed/33437810 http://dx.doi.org/10.21037/atm-20-2656 |
| work_keys_str_mv | AT borcomanedith keynote158studyfdagrantedacceleratedapprovalofpembrolizumabforthetreatmentofpatientswithadvancedpdl1positivecervicalcancer AT letourneauchristophe keynote158studyfdagrantedacceleratedapprovalofpembrolizumabforthetreatmentofpatientswithadvancedpdl1positivecervicalcancer |